Skip to main content
Blood Cancer Journal logoLink to Blood Cancer Journal
letter
. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

Ricardo D Parrondo 1, Keren Sam 1, Ahsan Rasheed 1, Victoria Alegria 1, Taimur Sher 1, Vivek Roy 1, Asher Chanan-Khan 1,2,3, Sikander Ailawadhi 1,2,
PMCID: PMC9019050  PMID: 35440072

The authors have retracted this Correspondence article because, after publication, they became aware that it inadvertently contains some data from a manuscript in preparation that will report the outcome of this clinical trial in full. In addition, as this article contains potentially identifying information, the content is no longer available online in order to protect patient confidentiality. All authors agree to this retraction.

Footnotes

The authors have retracted this Correspondence article because, after publication, they became aware that it inadvertently contains some data from a manuscript in preparation that will report the outcome of this clinical trial in full. In addition, as this article contains potentially identifying information, the content is no longer available online in order to protect patient confidentiality. All authors agree to this retraction.


Articles from Blood Cancer Journal are provided here courtesy of Nature Publishing Group

RESOURCES